ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...

Weekly Commentary: Infestation

With Credit blowups pressuring markets, we'll now see the typical dynamic where news/analysis follows market direction. Read ...
BMJ Open

Aerobic dance during chemotherapy in patients with breast cancer with cognitive impairment (ADANC): protocol for an assessor-blinded randomised clinical trial

Introduction Therapeutic exercise has been used to improve cancer-related dysfunction. Recent studies suggest that exercise after chemotherapy can improve cancer-related cognitive impairment. However, ...